Fluticasone Propionate Nasal Spray (Flixonase)
Is It Right for You?
A complete guide to Fluticasone Propionate Nasal Spray (Flixonase) — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Flixonase?
Flixonase is the brand name for fluticasone propionate 50 micrograms per actuation aqueous nasal spray, used for the prevention and treatment of seasonal and perennial allergic rhinitis in adults and children. It is one of the most prescribed and effective intranasal corticosteroid (INCS) sprays available in the UK, and is recommended by NICE and BSACI as the first-line pharmacological treatment for moderate-to-severe allergic rhinitis.
Fluticasone propionate nasal spray is also available in an over-the-counter formulation (Flixonase Nasules, Avamys — fluticasone furoate), but Flixonase on prescription ensures formal clinical diagnosis, dose guidance, assessment of response, and access for conditions such as nasal polyps where higher-dose intranasal corticosteroid use requires clinical oversight.
Flixonase is prescription-only in the UK for the management of nasal polyps. For allergic rhinitis, it is also available pharmacist-direct (OTC) for adults, though prescription supply ensures clinical review.
What Conditions Is Flixonase Used For?
Flixonase is indicated for:
first-line treatment for moderate-to-severe SAR; reduces all nasal symptoms including congestion, rhinorrhoea, sneezing, and itch, and has some effect on allergic conjunctivitis symptoms
year-round control of allergic rhinitis caused by persistent allergens (house dust mite, pet dander, mould)
reduction of nasal polyp size and associated symptoms (congestion, anosmia, rhinorrhoea); intranasal corticosteroids are first-line treatment for nasal polyps; Flixonase is licensed for this indication at higher doses (200 mcg per nostril twice daily) under prescription
intranasal corticosteroids are also effective for vasomotor (non-allergic) rhinitis and other non-IgE-mediated nasal inflammatory conditions
Flixonase does not provide immediate symptom relief — unlike oral antihistamines, which act within minutes. Its anti-inflammatory benefit accumulates over several days of consistent use. Starting Flixonase 1–2 weeks before the anticipated pollen season begins and using it daily throughout the season provides markedly better control than reactive, intermittent use.
How Does Flixonase Work?
Fluticasone propionate delivers its anti-allergic and anti-inflammatory effects directly to the nasal mucosa following intranasal administration:
Glucocorticoid receptor activation in nasal tissue: After intranasal spraying, fluticasone propionate is deposited on the nasal mucosa and binds intracellular glucocorticoid receptors in nasal epithelial cells, submucosal glands, mast cells, eosinophils, basophils, macrophages, and endothelial cells. Glucocorticoid receptor–fluticasone complexes translocate to the cell nucleus, where they bind glucocorticoid response elements on DNA, modulating the transcription of a broad range of genes.
Suppression of the full allergic inflammatory cascade: The net effect in the nasal mucosa is comprehensive suppression of both the early-phase IgE-mediated response and the late-phase eosinophilic inflammatory response: reduced histamine, leukotriene, and prostaglandin release; decreased mast cell and eosinophil numbers in nasal mucosa; reduced mucosal oedema through inhibition of vascular permeability; and reduced glandular secretion. This pan-inhibitory action is why intranasal corticosteroids address nasal congestion — which oral antihistamines treat poorly — as well as sneezing, rhinorrhoea, and nasal itch.
Minimal systemic bioavailability: Fluticasone propionate is formulated as an aqueous nasal spray and is designed for topical nasal delivery with minimal systemic absorption. The swallowed fraction undergoes extensive first-pass hepatic metabolism to inactive metabolites, and direct nasal bioavailability is less than 1%. This very low systemic exposure accounts for the excellent systemic safety profile of intranasal fluticasone at recommended doses.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Prime the pump before first use by pressing the actuator 6 times. Re-prime with 2 presses if unused for more than 30 days or if the pump has been left uncapped.
Blow the nose gently before using the spray. Clearing nasal passages improves drug deposition on the mucosa.
Correct spray technique is essential. Tilt the head slightly forward, insert the nozzle gently into one nostril, point the spray toward the outer wall of the nose (the lateral wall, not the septum), and spray while sniffing gently. Alternate nostrils without crossing over the nasal septum with the nozzle.
Do not aim the spray at the nasal septum. Repeatedly directing spray toward the septum causes irritation, mucosal drying, and — with prolonged use — risk of septal ulceration or perforation.
Start before the pollen season begins. The anti-inflammatory benefit of INCS develops over days; beginning treatment prophylactically provides much better season-long control than starting after symptoms are established.
Wipe the nozzle after each use and replace the cap to maintain hygiene and prevent nozzle blockage.
Side Effects of Flixonase
Most side effects are mild and resolve on their own. Serious side effects are rare but require immediate medical attention.
- Epistaxis (nosebleed) --- usually mild; risk is reduced by correct technique directed away from the septum.
- Nasal dryness, crusting, or mild burning on application.
- Unpleasant taste or smell.
- Headache.
- Nasal septal perforation --- rare; associated with prolonged use or incorrect technique.
- Glaucoma and posterior subcapsular cataracts --- rare; associated with prolonged high-dose use.
- Severe hypersensitivity reactions --- rare.
Directing Flixonase spray repeatedly at the septum leads to mucosal drying, ulceration, and — in rare cases — perforation. Every patient prescribed an intranasal corticosteroid must be trained in correct technique.
Drug Interactions
Most side effects are mild and resolve on their own. Serious side effects are rare but require immediate medical attention Flixonase
dramatically increase systemic fluticasone exposure even from intranasal administration; clinically significant adrenal suppression and Cushing's syndrome have been reported; avoid concurrent use; if unavoidable, use the lowest possible fluticasone dose with close monitoring.
may modestly increase systemic fluticasone exposure; clinically less significant at intranasal doses than with inhaled fluticasone but worth monitoring in patients on multiple corticosteroid preparations.
no significant pharmacokinetic interactions; allow a few minutes between using multiple intranasal sprays if more than one is prescribed.
Important Warnings
Correct intranasal spray technique is mandatory for safety and efficacy. Always direct the spray toward the lateral nasal wall, not the nasal septum. This single technique point prevents the most important local adverse effect (septal damage) and ensures optimal drug deposition on the allergic mucosa.
Patients on HIV protease inhibitor regimens containing ritonavir or cobicistat must not use fluticasone propionate in any formulation without specialist advice, due to the risk of severe adrenal suppression even from topical nasal preparations. An alternative intranasal corticosteroid less susceptible to this interaction (beclometasone, budesonide) should be considered.
In children on long-term intranasal corticosteroids, growth should be monitored regularly. Although the systemic exposure from intranasal fluticasone is very low, cumulative corticosteroid exposure from multiple sources (including INCS, ICS, and topical skin preparations) may be relevant in children.
Intranasal corticosteroids have very low systemic absorption and are preferred over oral antihistamines for allergic rhinitis in pregnancy. Flixonase is generally considered acceptable during pregnancy when clearly needed; discuss with your clinician. Systemic absorption is likely too low to affect breastfed infants at recommended doses.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Flixonase FAQs
Unlike antihistamine tablets, which block histamine receptors within minutes, intranasal corticosteroids work by suppressing the underlying allergic inflammatory process in the nasal mucosa — a process that takes several days of consistent treatment to become established. Most patients notice meaningful improvement after 3–7 days of regular use, with maximum benefit at 1–2 weeks. Starting 1–2 weeks before your pollen season begins, and using it every day throughout, provides the best possible control.
Rominent symptom — intranasal corticosteroids like Flixonase are more effective than oral antihistamine tablets and are recommended as the first-line treatment in current NICE and BSACI guidelines. Oral antihistamines are better for itchy eyes and skin symptoms, and for quick relief of acute symptoms. Many patients with moderate-to-severe hay fever benefit from combining both — Flixonase daily for nasal symptoms plus an oral antihistamine for breakthrough symptoms and eye involvement.
Yes. Intranasal corticosteroids including fluticasone propionate are the primary pharmacological treatment for nasal polyps, used to reduce polyp size, improve nasal airflow, and restore sense of smell. Higher doses (400 mcg/day) are typically used for polyp treatment compared to allergic rhinitis, under clinician supervision. If polyps are large, bilateral, or causing significant symptoms, ENT referral should be considered alongside medical management.
Mild, occasional nosebleeds are the most common side effect of intranasal corticosteroids and are usually caused by a combination of mucosal drying and incorrect spray technique directed at the nasal septum. Check your technique — aim toward the outer wall of the nostril, not the septum. Using a nasal moisturiser or saline spray before or after Flixonase can also help. If nosebleeds are frequent, heavy, or persistent, seek clinical review to examine the nasal mucosa.
Yes — intranasal fluticasone is safe for long-term daily use due to its very low systemic absorption (<1%). Annual clinical review is recommended to confirm ongoing benefit and to check for any local nasal side effects. There is no evidence of clinically significant adrenal suppression or systemic corticosteroid effects with long-term use at standard recommended doses, making it suitable for continuous perennial use.